Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $49.50 Consensus Target Price from Analysts

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the […]

Related Keywords

Blackrock ,Nova Scotia ,Canada ,United States ,Jamesm Frates ,Patrickd Yeramian , ,Institutional Trading Of Amylyx Pharmaceuticals ,News Ratings For Amylyx Pharmaceuticals Daily ,Amylyx Pharmaceuticals Inc ,Securities Exchange Commission ,Amylyx Pharmaceuticals Stock Performance ,Vanguard Group Inc ,Blackrock Inc ,Nasdaq ,Hermes Inc ,Analyst Recommendations For Amylyx Pharmaceuticals ,Citigroup ,Amylyx Pharmaceuticals ,Goldman Sachs Group ,Get Free Report ,Exchange Commission ,Pictet Asset Management ,Asset Management ,Get Free ,Amylyx Pharmaceuticals Daily ,Nasdaq Amlx ,Amlx ,Medical ,Ratings ,Consensus ,